Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1

Petr Jehlička, František Stožický, Otto Mayer Jr., Jana Varvařovská, Jaroslav Racek, Ladislav Trefil, K. Siala

. 2009 ; 58 (2) : 179-184.

Language English Country Czech Republic

A recently discussed cardiovascular risk factor, asymmetric dimethylarginine (ADMA), is known to act as an endogenous inhibitor of endothelial nitric oxide synthase. The aim of this study was to establish 1) the relationship between ADMA and ultrasonographically or biochemically determined endothelial dysfunction in children, and 2) the effect of folate supplementation on these parameters. The study cohort included 32 children with familial hypercholesterolemia (FH), 30 with diabetes mellitus type 1 (DM1) and 30 age-matched healthy children as the control group. Furthermore, twenty-eight randomly selected FH and DM1 children were re-examined after 3-months supplementation with folic acid. Baseline levels of ADMA and oxidized low density lipoproteins (oxLDL) were significantly higher in FH group than in DM1 and healthy children. Children in DM1 group had significantly lower concentration of homocysteine, but ADMA levels were normal. Folic acid supplementation significantly lowered homocysteine and hsCRP levels in both FH and DM1 group; however, ADMA and oxLDL concentrations remained unaltered. In conclusion, ADMA and oxLDL appear to be associated with endothelial dysfunction in children with FH. Administration of folic acid did not influence these markers in both FH and DM1 children.

References provided by Crossref.org

Bibliography, etc.

Lit.: 18

000      
00000naa 2200000 a 4500
001      
bmc07530673
003      
CZ-PrNML
005      
20111210151746.0
008      
091009s2009 xr e eng||
009      
AR
024    7_
$a 10.33549/physiolres.931418 $2 doi
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Jehlička, Petr $7 xx0105552
245    10
$a Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1 / $c Petr Jehlička, František Stožický, Otto Mayer Jr., Jana Varvařovská, Jaroslav Racek, Ladislav Trefil, K. Siala
314    __
$a Department of Pediatrics, Charles University in Prague, Plzeň JEHLICKA@fnplzen.cz
504    __
$a Lit.: 18
520    9_
$a A recently discussed cardiovascular risk factor, asymmetric dimethylarginine (ADMA), is known to act as an endogenous inhibitor of endothelial nitric oxide synthase. The aim of this study was to establish 1) the relationship between ADMA and ultrasonographically or biochemically determined endothelial dysfunction in children, and 2) the effect of folate supplementation on these parameters. The study cohort included 32 children with familial hypercholesterolemia (FH), 30 with diabetes mellitus type 1 (DM1) and 30 age-matched healthy children as the control group. Furthermore, twenty-eight randomly selected FH and DM1 children were re-examined after 3-months supplementation with folic acid. Baseline levels of ADMA and oxidized low density lipoproteins (oxLDL) were significantly higher in FH group than in DM1 and healthy children. Children in DM1 group had significantly lower concentration of homocysteine, but ADMA levels were normal. Folic acid supplementation significantly lowered homocysteine and hsCRP levels in both FH and DM1 group; however, ADMA and oxLDL concentrations remained unaltered. In conclusion, ADMA and oxLDL appear to be associated with endothelial dysfunction in children with FH. Administration of folic acid did not influence these markers in both FH and DM1 children.
650    _2
$a financování organizované $7 D005381
650    _2
$a mladiství $7 D000293
650    _2
$a anticholesteremika $x aplikace a dávkování $7 D000924
650    _2
$a arginin $x analogy a deriváty $x krev $7 D001120
650    _2
$a azetidiny $x aplikace a dávkování $7 D001384
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a dítě $7 D002648
650    _2
$a diabetes mellitus 1. typu $x metabolismus $7 D003922
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a cévní endotel $x metabolismus $x účinky léků $x ultrasonografie $7 D004730
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kyselina listová $x aplikace a dávkování $7 D005492
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x aplikace a dávkování $7 D019161
650    _2
$a hyperlipoproteinemie typ II $x epidemiologie $x farmakoterapie $x metabolismus $7 D006938
650    _2
$a lipoproteiny LDL $x krev $7 D008077
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a rizikové faktory $7 D012307
650    _2
$a vitamin B komplex $x aplikace a dávkování $7 D014803
700    1_
$a Stožický, František, $d 1941-2020 $7 jn20000710596
700    1_
$a Mayer, Otto, $d 1969- $7 xx0053346
700    1_
$a Varvařovská, Jana, $d 1951-2010 $7 xx0081920
700    1_
$a Racek, Jaroslav, $d 1951- $7 jn20000402090
700    1_
$a Trefil, Ladislav $7 xx0099653
700    1_
$a Siala, Konrad, $d 1971- $7 xx0136027
773    0_
$w MED00003824 $t Physiological research $g Roč. 58, č. 2 (2009), s. 179-184 $x 0862-8408
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/58/58_179.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 9
990    __
$a 20091009100046 $b ABA008
991    __
$a 20100430143300 $b ABA008
999    __
$a ok $b bmc $g 689199 $s 551040
BAS    __
$a 3
BMC    __
$a 2009 $b 58 $c 2 $d 179-184 $i 0862-8408 $m Physiological research $x MED00003824
LZP    __
$a 2009-32/mkme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...